EP Patent

EP2804851A1 — Therapeutically active compounds and their methods of use

Assigned to Agios Pharmaceuticals Inc · Expires 2014-11-26 · 11y expired

What this patent protects

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

USPTO Abstract

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Drugs covered by this patent

Patent Metadata

Patent number
EP2804851A1
Jurisdiction
EP
Classification
—
Expires
2014-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.